Compare ELAB & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELAB | CNSP |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2023 | 2019 |
| Metric | ELAB | CNSP |
|---|---|---|
| Price | $3.35 | $7.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 270.2K | 10.3K |
| Earning Date | 03-27-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $285,948.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $4.93 |
| 52 Week High | $99.72 | $114.00 |
| Indicator | ELAB | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 22.09 | 48.63 |
| Support Level | $4.89 | $6.11 |
| Resistance Level | $5.60 | $8.10 |
| Average True Range (ATR) | 0.44 | 0.52 |
| MACD | -0.15 | 0.13 |
| Stochastic Oscillator | 2.08 | 47.24 |
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.